Cathy Eng

List of Publications by Year
in descending order

243 papers	17,317 citations	19608 61 h-index	15218 126 g-index
266 all docs	266 docs citations	266 times ranked	18653 citing authors

#	Article	IF	Citations
1	First-in-Human PET Imaging and Estimated Radiation Dosimetry of l-[5-¹¹C]-Glutamine in Patients with Metastatic Colorectal Cancer. Journal of Nuclear Medicine, 2022, 63, 36-43.	2.8	13
2	Incorporating Reproductive Health in the Clinical Management of Early-Onset Colorectal Cancer. JCO Oncology Practice, 2022, 18, 169-172.	1.4	4
3	Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology. Journal of the National Cancer Institute, 2022, 114, 819-828.	3.0	2
4	Current treatment and future directions in the management of anal cancer. Ca-A Cancer Journal for Clinicians, 2022, 72, 183-195.	157.7	12
5	Trends in the Incidence and Treatment of Early-Onset Pancreatic Cancer. Cancers, 2022, 14, 283.	1.7	19
6	Targeted Fibroblast Growth Factor Receptor (FGFR) Inhibition in Recurrent, Metastatic Anal Carcinoma: A Case Report. Clinical Colorectal Cancer, 2022, , .	1.0	1
7	A comprehensive framework for early-onset colorectal cancer research. Lancet Oncology, The, 2022, 23, e116-e128.	5.1	49
8	Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution. Oncologist, 2022, 27, 40-47.	1.9	7
9	Age-standardised incidence rate and epidemiology of colorectal cancer in Africa: a systematic review and meta-analysis. BMJ Open, 2022, 12, e052376.	0.8	10
10	Clinical and pathologic features correlated with rare favorable survival in patients with BRAFV600E mutated colorectal cancer. Journal of Gastrointestinal Oncology, 2022, 13, 647-656.	0.6	2
11	A contemporary systematic review on liver transplantation for unresectable liver metastases of colorectal cancer. Cancer, 2022, 128, 2243-2257.	2.0	16
12	Microbiome Dynamics During Chemoradiation Therapy for Anal Cancer. International Journal of Radiation Oncology Biology Physics, 2022, 113, 974-984.	0.4	5
13	Colorectal Cancer Genomics by Genetic Ancestry. Cancer Discovery, 2022, 12, 1187-1188.	7.7	4
14	Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016. JAMA Network Open, 2022, 5, e2213588.	2.8	10
15	The Role of Immunotherapy in the Treatment of Anal Cancer and Future Strategies. Current Treatment Options in Oncology, 2022, 23, 1073-1085.	1.3	4
16	Anal Cancer: Emerging Standards in a Rare Disease. Journal of Clinical Oncology, 2022, 40, 2774-2788.	0.8	13
17	Sleep disturbance in patients with cancer: a feasibility study of multimodal therapy. BMJ Supportive and Palliative Care, 2021, 11, 170-179.	0.8	14
18	Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer. Oncologist, 2021, 26, e261-e269.	1.9	10

#	Article	IF	Citations
19	The prognostic impact of RAS on overall survival following liver resection in early versus late-onset colorectal cancer patients. British Journal of Cancer, 2021, 124, 797-804.	2.9	16
20	Moving Beyond the Momentum: Innovative Approaches to Clinical Trial Implementation. JCO Oncology Practice, 2021, 17, 607-614.	1.4	7
21	BRAF V600E mutated metastatic colorectal cancer: current progress and future directions. Expert Opinion on Biological Therapy, 2021, 21, 1311-1313.	1.4	1
22	Pancreatic Cancer in Young Adults: Can Innovative Approaches Lead to Better Outcomes?. Journal of the National Cancer Institute, 2021, 113, 1125-1126.	3.0	1
23	Safety considerations with new treatment regimens for anal cancer. Expert Opinion on Drug Safety, 2021, 20, 889-902.	1.0	2
24	Immunotherapy for GI Cancers. Advances in Oncology, 2021, 1, 283-295.	0.1	0
25	CEA as a blood-based biomarker in anal cancer. Oncotarget, 2021, 12, 1037-1045.	0.8	4
26	Surgical resection and survival outcomes in metastatic young adult colorectal cancer patients. Cancer Medicine, 2021, 10, 4269-4281.	1.3	8
27	Abstract 101: Racial differences in somatic mutations among patients with early-onset colorectal cancer. , 2021, , .		1
28	Colorectal cancer adjuvant chemotherapy trends among a nonelderly veteran cohort at a southern veterans health administration. Cancer Reports, 2021, , e1508.	0.6	1
29	Early-Onset Colorectal Cancer: The Mystery Remains. Journal of the National Cancer Institute, 2021, 113, 1608-1610.	3.0	6
30	FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer. Future Oncology, 2021, 17, 3151-3162.	1.1	14
31	Squamous Cell Carcinoma of the Anal Verge with Sigmoid Colon Metastasis. Clinical Colorectal Cancer, 2021, 20, e210-e213.	1.0	0
32	Cutaneous Lymphangitic Carcinomatosis as the First Sign of Recurrent Malignancy in a Patient With a History of Rectal Adenocarcinoma. Clinical Colorectal Cancer, 2021, 20, 368-371.	1.0	1
33	Antiemetics: ASCO Guideline Update. Journal of Clinical Oncology, 2020, 38, 2782-2797.	0.8	201
34	Up-and-Coming Experimental Drug Options for Metastatic Colorectal Cancer . Journal of Experimental Pharmacology, 2020, Volume 12, 475-485.	1.5	7
35	Integrated clinico-molecular profiling of appendiceal adenocarcinoma reveals a unique grade-driven entity distinct from colorectal cancer. British Journal of Cancer, 2020, 123, 1262-1270.	2.9	18
36	Reply to S. Boutayeb et al. JCO Oncology Practice, 2020, 16, 525-525.	1.4	1

#	Article	IF	Citations
37	Outcomes with anti-EGFR monoclonal antibodies in metastatic and recurrent anal squamous cell carcinoma. Expert Review of Anticancer Therapy, 2020, 20, 901-908.	1.1	7
38	Neoadjuvant Chemotherapy for Colon Cancer. Cancers, 2020, 12, 2368.	1.7	18
39	Anal cancer treatment regimen considerations for the COVID-19 era: In regard to Tchelebi et al. Radiotherapy and Oncology, 2020, 151, 56-57.	0.3	1
40	In Reply. Oncologist, 2020, 25, e1252-e1253.	1.9	0
41	International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct. Journal of Clinical Oncology, 2020, 38, 2510-2518.	0.8	92
42	Evolution of Cancer Care in Response to the COVID â€19 Pandemic. Oncologist, 2020, 25, e1426-e1427.	1.9	7
43	Bevacizumab Does Not Influence the Efficacy of Partial Splenic Embolization in the Management of Chemotherapy-Induced Hypersplenism. Clinical Colorectal Cancer, 2020, 19, e189-e199.	1.0	1
44	FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival. Clinical Colorectal Cancer, 2020, 19, 248-255.e6.	1.0	3
45	Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. Clinical Cancer Research, 2020, 26, 1924-1931.	3.2	50
46	A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group. Oncologist, 2020, 25, e936-e945.	1.9	520
47	ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectalâ€“Anal Task Forces whitepaper. Nature Reviews Clinical Oncology, 2020, 17, 757-770.	12.5	218
48	Phase I study of DFP-11207, a novel oral fluoropyrimidine with reasonable AUC and low Cmax and improved tolerability, in patients with solid tumors. Investigational New Drugs, 2020, 38, 1763-1773.	1.2	3
49	Early-Onset Appendiceal Cancer Survival by Race or Ethnicity in the United States. Gastroenterology, 2020, 159, 1605-1608.	0.6	10
50	Shanghai international consensus on diagnosis and comprehensive treatment of colorectal liver metastases (version 2019). European Journal of Surgical Oncology, 2020, 46, 955-966.	0.5	22
51	TAS-102 plus bevacizumab: a new standard for metastatic colorectal cancer?. Lancet Oncology, The, 2020, 21, 326-327.	5.1	1
52	Spectrum of Somatic Cancer Gene Variations Among Adults With Appendiceal Cancer by Age. JAMA Network Open, 2020, 3, e2028644.	2.8	9
53	A phase II study of axalimogene filolisbac for patients with previously treated, unresectable, persistent/recurrent loco-regional or metastatic anal cancer. Oncotarget, 2020, 11, 1334-1343.	0.8	18
54	418â€…A phase 1, dose escalation and dose expansion study of SQZ PBMC HPV as monotherapy and in combination with atezolizumab in HLA-A*02+ Patients with HPV16+ recurrent, or metastatic solid tumors. , 2020, , .		0

#	Article	IF	Citations
55	Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma. British Journal of Cancer, 2019, 121, 505-510.	2.9	32
56	More questions regarding HIPEC in colorectal carcinomatosis. The Lancet Gastroenterology and Hepatology, 2019, 4, 744-745.	3.7	3
57	A Phase II Study of Capecitabine/Oxaliplatin With Concurrent Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Anal Canal. Clinical Colorectal Cancer, 2019, 18, 301-306.	1.0	7
58	Comprehensive Genomic Landscapes in Early and Later Onset Colorectal Cancer. Clinical Cancer Research, 2019, 25, 5852-5858.	3.2	116
59	Minocycline for Symptom Reduction During Oxaliplatin-Based Chemotherapy for Colorectal Cancer: A Phase II Randomized Clinical Trial. Journal of Pain and Symptom Management, 2019, 58, 662-671.	0.6	17
60	Role of immune checkpoint inhibitors in the treatment of colorectal cancer: focus on nivolumab. Expert Opinion on Biological Therapy, 2019, 19, 1247-1263.	1.4	29
61	Pharmacotherapeutic considerations for elderly patients with colorectal cancer. Expert Opinion on Pharmacotherapy, 2019, 20, 2139-2160.	0.9	2
62	The Management and Prevention of Anal Squamous Cell Carcinoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 216-225.	1.8	18
63	Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncology, The, 2019, 20, 849-861.	5.1	368
64	Identification of Actionable Genomic Alterations Using Circulating Cell-Free DNA. JCO Precision Oncology, 2019, 3, 1-10.	1.5	6
65	Atypical, Non-V600 BRAF Mutations as a Potential Mechanism of Resistance to EGFR Inhibition in Metastatic Colorectal Cancer. JCO Precision Oncology, 2019, 3, 1-10.	1.5	12
66	Current synthetic pharmacotherapy for treatment-resistant colorectal cancer: when urgent action is required. Expert Opinion on Pharmacotherapy, 2019, 20, 523-534.	0.9	3
67	Deleterious Effect of RAS and Evolutionary High-risk TP53 Double Mutation in Colorectal Liver Metastases. Annals of Surgery, 2019, 269, 917-923.	2.1	121
68	Managing Non-Hepatic Metastatic Sites: Lung and CNS. , 2019, , 495-508.		0
69	Squamous Cell Carcinoma of the Anal Canal. , 2019, , 175-184.		0
70	Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma. Clinical Cancer Research, 2018, 24, 3263-3272.	3.2	61
71	The Long-Term Impact of Neurofeedback on Symptom Burden and Interference in Patients With Chronic Chemotherapy-Induced Neuropathy: Analysis of a Randomized Controlled Trial. Journal of Pain and Symptom Management, 2018, 55, 1276-1285.	0.6	33
72	Role of Chemotherapy in the Neoadjuvant/Adjuvant Setting for Patients With Rectal Adenocarcinoma Undergoing Chemoradiotherapy and Surgery or Radiotherapy and Surgery. Current Oncology Reports, 2018, 20, 3.	1.8	11

#	Article	IF	Citations
73	Hyperfractionated Accelerated Reirradiation for Patients With Recurrent Anal Cancer Previously Treated With Definitive Chemoradiation. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 632-637.	0.6	14
74	Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers. Clinical Cancer Research, 2018, 24, 181-188.	3.2	127
75	Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab. Gut, 2018, 67, 1095-1102.	6.1	19
76	Physician interpretation of genomic test results and treatment selection. Cancer, 2018, 124, 966-972.	2.0	10
77	Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes. Clinical Cancer Research, 2018, 24, 1062-1072.	3.2	225
78	Models to Predict Hepatitis B Virus Infection Among Patients With Cancer Undergoing Systemic Anticancer Therapy: A Prospective Cohort Study. Journal of Clinical Oncology, 2018, 36, 959-967.	0.8	18
79	Experimental and investigational drugs for the treatment of anal cancer. Expert Opinion on Investigational Drugs, 2018, 27, 941-950.	1.9	4
80	Genetic susceptibility markers for a breast-colorectal cancer phenotype: Exploratory results from genome-wide association studies. PLoS ONE, 2018, 13, e0196245.	1.1	9
81	Extended-Field Chemoradiation Therapy for Definitive Treatment of Anal Canal Squamous Cell Carcinoma Involving the Para-Aortic Lymph Nodes. International Journal of Radiation Oncology Biology Physics, 2018, 102, 102-108.	0.4	19
82	Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. European Journal of Cancer, 2018, 100, 35-45.	1.3	29
83	Role of Immunotherapy in the Treatment of Squamous Cell Carcinoma of the Anal Canal. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 903-908.	2.3	10
84	Minimally invasive management of the entire treatment sequence in patients with stage IV colorectal cancer: a propensity-score weighting analysis. Hpb, 2018, 20, 1150-1156.	0.1	10
85	Treatment of primary rectal adenocarcinoma after prior pelvic radiation: The role of hyperfractionated accelerated reirradiation. Advances in Radiation Oncology, 2018, 3, 595-600.	0.6	4
86	Definitive Chemoradiation for Squamous Cell Carcinoma of the Rectum. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 163-166.	0.6	24
87	Oncologic and Functional Hazards of Obesity Among Patients With Locally Advanced Rectal Cancer Following Neoadjuvant Chemoradiation Therapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 277-282.	0.6	20
88	Preface. Surgical Oncology Clinics of North America, 2017, 26, xv-xvi.	0.6	0
89	Hyperfractionated accelerated reirradiation for rectal cancer: An analysis of outcomes and toxicity. Radiotherapy and Oncology, 2017, 122, 146-151.	0.3	45
90	Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncology, The, 2017, 18, 446-453.	5.1	322

#	Article	IF	Citations
91	Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. Clinical Cancer Research, 2017, 23, 4146-4154.	3.2	50
92	Randomized controlled trial of neurofeedback on chemotherapyâ€induced peripheral neuropathy: A pilot study. Cancer, 2017, 123, 1989-1997.	2.0	43
93	Preoperative radiation dose escalation for rectal cancer using a concomitant boost strategy improves tumor downstaging without increasing toxicity: A matched-pair analysis. Advances in Radiation Oncology, 2017, 2, 455-464.	0.6	18
94	Impact of the timing of hepatitis B virus identification and antiâ€“hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy. Cancer, 2017, 123, 3367-3376.	2.0	13
95	Total Laparoscopic Management for Stage IV Colorectal Cancer Requiring Multivisceral Resection. Annals of Surgical Oncology, 2017, 24, 2595-2595.	0.7	3
96	Measurement of DNA damage in peripheral blood by the Î³-H2AX assay as predictor of colorectal cancer risk. DNA Repair, 2017, 53, 24-30.	1.3	15
97	Utility of Appendiceal Calcifications Detected on Computed Tomography as a Predictor for an Underlying Appendiceal Epithelial Neoplasm. Annals of Surgical Oncology, 2017, 24, 3667-3672.	0.7	7
98	Proteomic Features of Colorectal Cancer Identify Tumor Subtypes Independent of Oncogenic Mutations and Independently Predict Relapse-Free Survival. Annals of Surgical Oncology, 2017, 24, 4051-4058.	0.7	32
99	Pharmacotherapy of Anal Cancer. Drugs, 2017, 77, 1519-1530.	4.9	6
100	Comprehensive Genomic Profiling of Metastatic Squamous Cell Carcinoma of the Anal Canal. Molecular Cancer Research, 2017, 15, 1542-1550.	1.5	59
101	Neoadjuvant Strategies: Locally Advanced Rectal Cancer. Clinics in Colon and Rectal Surgery, 2017, 30, 383-386.	0.5	9
102	Global and targeted serum metabolic profiling of colorectal cancer progression. Cancer, 2017, 123, 4066-4074.	2.0	51
103	Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Moderately and Poorly Differentiated Appendiceal Adenocarcinoma: Survival Outcomes and Patient Selection. Annals of Surgical Oncology, 2017, 24, 2646-2654.	0.7	30
104	Retrospective study of nonmucinous appendiceal adenocarcinomas: role of systemic chemotherapy and cytoreductive surgery. BMC Cancer, 2017, 17, 331.	1.1	11
105	Low-grade Appendiceal Mucinous Neoplasm of Uncertain Malignant Potential (LAMN-UMP): Prognostic Factors and Implications for Treatment and Follow-up. Annals of Surgical Oncology, 2017, 24, 187-193.	0.7	62
106	Total Transthoracic Approach Facilitates Laparoscopic Hepatic Resection in Patients with Significant Prior Abdominal Surgery. Annals of Surgical Oncology, 2017, 24, 1376-1377.	0.7	10
107	Metastatic Anal Cancer and Novel Agents. Surgical Oncology Clinics of North America, 2017, 26, 133-142.	0.6	7
108	Clinical utility of circulating cell-free DNA in advanced colorectal cancer. PLoS ONE, 2017, 12, e0183949.	1.1	25

#	Article	IF	Citations
109	Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology, 2017, 35, 3240-3261.	0.8	454
110	Impact of Recurrence and Salvage Surgery on Survival After Multidisciplinary Treatment of Rectal Cancer. Journal of Clinical Oncology, 2017, 35, 2631-2638.	0.8	62
111	First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. JCI Insight, 2017, 2, .	2.3	26
112	Short course radiation as a component of definitive multidisciplinary treatment for select patients with metastatic rectal adenocarcinoma. Journal of Gastrointestinal Oncology, 2017, 8, 990-997.	0.6	19
113	Metastasis regulation by PPARD expression in cancer cells. JCI Insight, 2017, 2, e91419.	2.3	58
114	Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. PLoS ONE, 2017, 12, e0173345.	1.1	65
115	FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. Oncotarget, 2017, 8, 39268-39279.	0.8	69
116	The promise of immunotherapy in anal squamous cell carcinoma: a novel approach for an orphan disease. Clinical Advances in Hematology and Oncology, 2017, 15, 968-961.	0.3	4
117	Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin. Oncotarget, 2016, 7, 67495-67506.	0.8	42
118	MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon. Oncotarget, 2016, 7, 54627-54631.	0.8	53
119	Summary of emerging targets in anal cancer: the case for an immunotherapy based-approach. Journal of Gastrointestinal Oncology, 2016, 7, 721-726.	0.6	7
120	Epidermal growth factor receptor inhibition in metastatic anal cancer. Anti-Cancer Drugs, 2016, 27, 804-808.	0.7	26
121	The Treatment of Colorectal Cancer During Pregnancy: Cytotoxic Chemotherapy and Targeted Therapy Challenges. Oncologist, 2016, 21, 563-570.	1.9	40
122	Prechemotherapy Touch Sensation Deficits Predict Oxaliplatin-Induced Neuropathy in Patients with Colorectal Cancer. Oncology, 2016, 90, 127-135.	0.9	25
123	American Society of Clinical Oncology Statement: Human Papillomavirus Vaccination for Cancer Prevention. Journal of Clinical Oncology, 2016, 34, 1803-1812.	0.8	83
124	POLE mutations in colorectal cancer: a new biomarker?. The Lancet Gastroenterology and Hepatology, 2016, 1, 176-177.	3.7	9
125	Multidisciplinary management of stage IV colon cancer. Seminars in Colon and Rectal Surgery, 2016, 27, 213-218.	0.2	2
126	A randomized, placeboâ€controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wildâ€type KRAS who have received firstâ€line systemic therapy. International Journal of Cancer, 2016, 139, 177-186.	2.3	52

#	Article	IF	Citations
127	Serum exosomal miR-4772-3p is a predictor of tumor recurrence in stage II and III colon cancer. Oncotarget, 2016, 7, 76250-76260.	0.8	93
128	Clinicopathologic Features Associated With Human Papillomavirus/p16 in Patients With Metastatic Squamous Cell Carcinoma of the Anal Canal. Oncologist, 2015, 20, 1247-1252.	1.9	28
129	Overtreatment of Young Adults With Colon Cancer. JAMA Surgery, 2015, 150, 402.	2.2	180
130	Potential Prognostic Impact of Baseline CEA Level and Surgery of Primary Tumor Among Patients with Synchronous Stage IV Colorectal Cancer: A Large Population Based Study. Indian Journal of Surgical Oncology, 2015, 6, 198-206.	0.3	9
131	Clinical trial designs for rare diseases: Studies developed and discussed by the International Rare Cancers Initiative. European Journal of Cancer, 2015, 51, 271-281.	1.3	108
132	Challenges of Efficacy Assessments in Pseudomyxoma Peritonea. Oncologist, 2015, 20, e3-4.	1.9	3
133	Circulating DNA biomarkers: a primer for metastatic colorectal cancer?. Lancet Oncology, The, 2015, 16, 878-879.	5.1	3
134	Colorectal Cancer Survivorship Management. , 2015, , 71-93.		0
135	Quality of life after intensity-modulated radiation therapy for anal cancer. Journal of Radiation Oncology, 2015, 4, 291-298.	0.7	7
136	Perspectives on Clinical Trials for Gastrointestinal Malignancies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , 40-43.	1.8	1
137	Cetuximab in combination with cisplatin and 5-Fluorouracil induces dramatic response in metastatic refractory squamous cell carcinoma of the anal canal. Journal of Gastrointestinal Oncology, 2015, 6, E82-5.	0.6	4
138	Perioperative systemic chemotherapy for appendiceal mucinous carcinoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Journal of Surgical Oncology, 2014, 109, 740-745.	0.8	75
139	A Quantitative Sensory Analysis of Peripheral Neuropathy in Colorectal Cancer and Its Exacerbation by Oxaliplatin Chemotherapy. Cancer Research, 2014, 74, 5955-5962.	0.4	57
140	Association of Age With Survival in Patients With Metastatic Colorectal Cancer: Analysis From the ARCAD Clinical Trials Program. Journal of Clinical Oncology, 2014, 32, 2975-2982.	0.8	118
141	Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer. Clinical Cancer Research, 2014, 20, 4240-4250.	3.2	102
142	Intensity-modulated Radiation Therapy With Concurrent Chemotherapy for Anal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 461-466.	0.6	65
143	Preoperative Radiation Therapy With Concurrent Capecitabine, Bevacizumab, and Erlotinib for Rectal Cancer: A Phase 1 Trial. International Journal of Radiation Oncology Biology Physics, 2014, 88, 301-305.	0.4	21
144	Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial. Supportive Care in Cancer, 2014, 22, 1223-1231.	1.0	86

#	Article	IF	Citations
145	Atypical Metastatic Presentations in Colorectal Cancer: A Case Series. Clinical Colorectal Cancer, 2014, 13, e1-e4.	1.0	9
146	Optimal management of squamous cell carcinoma of the anal canal: where are we now?. Expert Review of Anticancer Therapy, 2014, 14, 877-886.	1.1	7
147	Optimal Treatment Strategies for Anal Cancer. Current Treatment Options in Oncology, 2014, 15, 443-455.	1.3	6
148	Cetuximab in Refractory Squamous Cell Carcinoma of the Anal Canal. Journal of Gastrointestinal Cancer, 2014, 45, 198-200.	0.6	7
149	Progression-Free Survival Remains Poor Over Sequential Lines of Systemic Therapy in Patients With BRAF-Mutated Colorectal Cancer. Clinical Colorectal Cancer, 2014, 13, 164-171.	1.0	108
150	Postoperative chemotherapy use after neoadjuvant chemoradiotherapy for rectal cancer: Analysis of Surveillance, Epidemiology, and End Resultsâ€“Medicare data, 1998â€“2007. Cancer, 2014, 120, 1162-1170.	2.0	43
151	Preoperative chemotherapy prior to pulmonary metastasectomy in surgically resected primary colorectal carcinoma. Oncotarget, 2014, 5, 6584-6593.	0.8	14
152	The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal. Oncotarget, 2014, 5, 11133-11142.	0.8	102
153	Definitive chemoradiation in oligometastatic squamous cell carcinoma of the anal canal. Gastrointestinal Cancer Research: GCR, 2014, 7, 65-8.	0.8	4
154	Long-term results of weekly/daily cisplatin-based chemoradiation for locally advanced squamous cell carcinoma of the anal canal. Cancer, 2013, 119, 3769-3775.	2.0	27
155	Will PICCOLO affect metastatic colorectal cancer therapy?. Lancet Oncology, The, 2013, 14, 679-680.	5.1	0
156	Quantified pathologic response assessed as residual tumor burden is a predictor of recurrenceâ€free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy. Cancer, 2013, 119, 4231-4241.	2.0	52
157	Pathologic complete response in poorly differentiated adenocarcinomas of the appendix: A case series. Acta OncolÃ³gica, 2013, 52, 1044-1046.	0.8	2
158	Impact of Molecular Alterations and Targeted Therapy in Appendiceal Adenocarcinomas. Oncologist, 2013, 18, 1270-1277.	1.9	41
159	Metformin use and improved response to therapy in rectal cancer. Cancer Medicine, 2013, 2, 99-107.	1.3	85
160	Improving the AJCC/TNM Staging for Adenocarcinomas of the Appendix. Annals of Surgery, 2013, 257, 1072-1078.	2.1	91
161	The Association of Alternate VEGF Ligands with Resistance to Anti-VEGF Therapy in Metastatic Colorectal Cancer. PLoS ONE, 2013, 8, e77117.	1.1	106
162	The natural history and role of surgical cytoreduction and systemic chemotherapy in high-grade mucinous adenocarcinomas of the appendix.. Journal of Clinical Oncology, 2013, 31, 199-199.	0.8	1

#	Article	IF	Citations
163	Genetic Polymorphisms in MicroRNA-Related Genes as Predictors of Clinical Outcomes in Colorectal Adenocarcinoma Patients. Clinical Cancer Research, 2012, 18, 3982-3991.	3.2	67
164	Genomic analysis and selected molecular pathways in rare cancers. Physical Biology, 2012, 9, 065004.	0.8	8
165	Subclinical Peripheral Neuropathy Is a Common Finding in Colorectal Cancer Patients Prior to Chemotherapy. Clinical Cancer Research, 2012, 18, 3180-3187.	3.2	55
166	The Current State of Targeted Agents in Rectal Cancer. International Journal of Surgical Oncology, 2012, 2012, 1-14.	0.3	8
167	Genetic variants within ultraconserved elements and susceptibility to right- and left-sided colorectal adenocarcinoma. Carcinogenesis, 2012, 33, 841-847.	1.3	7
168	Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of colorectal cancer. Colorectal Cancer, 2012, 1, 15-16.	0.8	0
169	GWAS-identified colorectal cancer susceptibility loci associated with clinical outcomes. Carcinogenesis, 2012, 33, 1327-1331.	1.3	46
170	Perifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 623-633.	1.5	90
171	Survival Benefit Associated With Surgical Oophorectomy in Patients With Colorectal Cancer Metastatic to the Ovary. Clinical Colorectal Cancer, 2012, 11, 191-194.	1.0	22
172	Neoadjuvant Treatment Response As an Early Response Indicator for Patients With Rectal Cancer. Journal of Clinical Oncology, 2012, 30, 1770-1776.	0.8	427
173	The promise of mTOR inhibitors in the treatment of colorectal cancer. Expert Opinion on Investigational Drugs, 2012, 21, 1775-1788.	1.9	26
174	Role of the METâ€“HGF axis in colorectal cancer: precepts and prospects. Colorectal Cancer, 2012, 1, 329-341.	0.8	6
175	Clinical Implications of Circulating Tumor Cells in Advanced Colorectal Cancer. Current Colorectal Cancer Reports, 2012, 8, 233-242.	1.0	0
176	Identification of polymorphisms in ultraconserved elements associated with clinical outcomes in locally advanced colorectal adenocarcinoma. Cancer, 2012, 118, 6188-6198.	2.0	14
177	SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma. Investigational New Drugs, 2012, 30, 1646-1651.	1.2	135
178	Intensity-modulated radiation therapy (IMRT) with concurrent chemotherapy for anal cancer: A large single-institution experience.. Journal of Clinical Oncology, 2012, 30, 661-661.	0.8	3
179	A phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory metastatic colorectal cancer.. Journal of Clinical Oncology, 2012, 30, 450-450.	0.8	0
180	Management of Refractory Metastatic Anal Squamous Cell Carcinoma Following Disease Progression on Traditional Chemoradiation Therapy. Journal of the Advanced Practitioner in Oncology, 2012, 3, 161-9.	0.2	2

#	Article	IF	Citations
181	Cetuximab in the treatment of patients with colorectal cancer. Expert Opinion on Biological Therapy, 2011, 11, 937-949.	1.4	48
182	The current landscape of locally advanced rectal cancer. Nature Reviews Clinical Oncology, 2011, 8, 649-659.	12.5	76
183	Fatal Diffuse Alveolar Damage Associated with Oxaliplatin Administration. Clinical Colorectal Cancer, 2011, 10, 198-202.	1.0	16
184	Multidetector Computed Tomography Follow-up of Hypoattenuating Small Liver Lesions in Patients With Rectal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 411-416.	0.6	10
185	Number of lymph nodes examined and prognosis among pathologically lymph node-negative patients after preoperative chemoradiation therapy for rectal adenocarcinoma. Cancer, 2011, 117, 3713-3722.	2.0	51
186	A Novel Platform for Detection of CK+ and CKâ^' CTCs. Cancer Discovery, 2011, 1, 580-586.	7.7	189
187	High Survival Rate After Two-Stage Resection of Advanced Colorectal Liver Metastases: Response-Based Selection and Complete Resection Define Outcome. Journal of Clinical Oncology, 2011, 29, 1083-1090.	0.8	367
188	Association of CHFR Promoter Methylation with Disease Recurrence in Locally Advanced Colon Cancer. Clinical Cancer Research, 2011, 17, 4531-4540.	3.2	32
189	Trends in Colorectal Cancer Incidence by Anatomic Site and Disease Stage in the United States From 1976 to 2005. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 573-580.	0.6	187
190	Carcinoma of the anal canal: small steps in treatment advances. Clinical Advances in Hematology and Oncology, 2011, 9, 662-9.	0.3	0
191	Long-Term Survival and Recurrence Outcomes Following Surgery for Distal Rectal Cancer. Annals of Surgical Oncology, 2010, 17, 2863-2869.	0.7	100
192	Phase II Trial of Neoadjuvant Bevacizumab, Capecitabine, and Radiotherapy for Locally Advanced Rectal Cancer. International Journal of Radiation Oncology Biology Physics, 2010, 76, 824-830.	0.4	177
193	Molecular Biomarkers Correlate with Disease-Free Survival in Patients with Anal Canal Carcinoma Treated with Chemoradiation. Digestive Diseases and Sciences, 2010, 55, 1098-1105.	1.1	50
194	Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin. Cancer, 2010, 116, 316-322.	2.0	109
195	Longâ€term quality of life after radiotherapy for the treatment of anal cancer. Cancer, 2010, 116, 822-829.	2.0	106
196	Validation and application of a module of the M. D. Anderson Symptom Inventory for measuring multiple symptoms in patients with gastrointestinal cancer (the MDASIâ€GI). Cancer, 2010, 116, 2053-2063.	2.0	79
197	A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5â€fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver. Cancer, 2010, 116, 4086-4094.	2.0	26
198	Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer. Cancer, 2010, 116, 5325-5335.	2.0	77

#	Article	IF	Citations
199	Interactions between cigarette smoking and selected polymorphisms in xenobiotic metabolizing enzymes in risk for colorectal cancer: A caseâ€only analysis. Molecular Carcinogenesis, 2010, 49, 974-980.	1.3	13
200	Hyperfractionated Accelerated Radiotherapy for Rectal Cancer in Patients With Prior Pelvic Irradiation. International Journal of Radiation Oncology Biology Physics, 2010, 77, 60-65.	0.4	115
201	American Society of Clinical Oncology 2009 Clinical Evidence Review on Radiofrequency Ablation of Hepatic Metastases From Colorectal Cancer. Journal of Clinical Oncology, 2010, 28, 493-508.	0.8	399
202	Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance. Journal of Clinical Oncology, 2010, 28, 453-459.	0.8	440
203	The Evolving Role of Monoclonal Antibodies in Colorectal Cancer: Early Presumptions and Impact on Clinical Trial Development. Oncologist, 2010, 15, 73-84.	1.9	42
204	Are Herbal Medicines Ripe for the Cancer Clinic?. Science Translational Medicine, 2010, 2, 45ps41.	5.8	14
205	Oxaliplatin-Mediated Increase in Spleen Size As a Biomarker for the Development of Hepatic Sinusoidal Injury. Journal of Clinical Oncology, 2010, 28, 2549-2555.	0.8	188
206	Commentary: Practice Patterns and Potential Impact on Quality Measures for a Practicing Physician. Journal of Oncology Practice, 2009, 5, 233-235.	2.5	2
207	Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy. Journal of Clinical Oncology, 2009, 27, 3677-3683.	0.8	1,166
208	Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer. Nature Reviews Clinical Oncology, 2009, 6, 207-218.	12.5	61
209	Should cisplatin be avoided in the treatment of locally advanced squamous cell carcinoma of the anal canal?. Nature Reviews Gastroenterology & Hepatology, 2009, 6, 16-17.	1.7	3
210	Practical Application of a Calculator for Conditional Survival in Colon Cancer. Journal of Clinical Oncology, 2009, 27, 5938-5943.	0.8	95
211	Phase II Study of Capecitabine and Oxaliplatin for Advanced Adenocarcinoma of the Small Bowel and Ampulla of Vater. Journal of Clinical Oncology, 2009, 27, 2598-2603.	0.8	208
212	Lymph node status after neoadjuvant radiotherapy for rectal cancer is a biologic predictor of outcome. Cancer, 2009, 115, 5432-5440.	2.0	65
213	Sacral Insufficiency Fractures After Preoperative Chemoradiation for Rectal Cancer: Incidence, Risk Factors, and Clinical Course. International Journal of Radiation Oncology Biology Physics, 2009, 74, 818-823.	0.4	55
214	Intensity-Modulated Radiation Therapy for the Treatment of Squamous Cell Anal Cancer With Para-aortic Nodal Involvement. International Journal of Radiation Oncology Biology Physics, 2009, 75, 791-794.	0.4	29
215	Incidence, Risk Factors, and Impact of Severe Neutropenia After Hyperthermic Intraperitoneal Mitomycin C. Annals of Surgical Oncology, 2009, 16, 2181-2187.	0.7	64
216	A Twenty-Year Experience with Adenocarcinoma of the Anal Canal. Diseases of the Colon and Rectum, 2009, 52, 1375-1380.	0.7	56

#	Article	IF	Citations
217	Treatment Options in Metastatic Squamous Cell Carcinoma of the Anal Canal. Current Treatment Options in Oncology, 2008, 9, 400-407.	1.3	18
218	Patterns of Locoregional Recurrence After Surgery and Radiotherapy or Chemoradiation for Rectal Cancer. International Journal of Radiation Oncology Biology Physics, 2008, 71, 1175-1180.	0.4	74
219	Second-Line Chemotherapy Use in Metastatic Colon Cancer Varies by Disease Responsiveness. Clinical Colorectal Cancer, 2008, 7, 55-59.	1.0	6
220	Bevacizumab in the Treatment of a Patient with Metastatic Colorectal Carcinoma with Brain Metastases. Clinical Colorectal Cancer, 2008, 7, 65-68.	1.0	26
221	Aggressive Combined Modality Therapy for Recurrent Colorectal Cancer Involving the Duodenum and Pancreas: A Report of 5 Cases. Clinical Colorectal Cancer, 2008, 7, 338-342.	1.0	0
222	EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2008, 26, 2311-2319.	0.8	884
223	Systematic Survey of Therapeutic Trials for Metastatic Colorectal Cancer: Room for Improvement in the Critical Pathway. Journal of Clinical Oncology, 2008, 26, 2000-2005.	0.8	16
224	Emerging drugs for colorectal cancer. Expert Opinion on Emerging Drugs, 2008, 13, 629-642.	1.0	10
225	Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point After Resection of Hepatic Colorectal Metastases. Journal of Clinical Oncology, 2008, 26, 5344-5351.	0.8	548
226	Prognostic factors for squamous cell cancer of the anal canal. Gastrointestinal Cancer Research: GCR, 2008, 2, 10-4.	0.8	16
227	K-Ras and sensitivity to EGFR inhibitors in metastatic colorectal cancer. Clinical Advances in Hematology and Oncology, 2008, 6, 174-5.	0.3	6
228	Combining Targeted Therapies to Enhance the Effectiveness of Chemotherapy in Patients with Treatment-Refractory Colorectal Cancer. Clinical Colorectal Cancer, 2007, 6, S53-S59.	1.0	2
229	Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. Cancer, 2007, 109, 1750-1755.	2.0	294
230	Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatinâ€based chemotherapy for colorectal liver metastases. Cancer, 2007, 110, 2761-2767.	2.0	347
231	Predictors and Patterns of Recurrence After Definitive Chemoradiation for Anal Cancer. International Journal of Radiation Oncology Biology Physics, 2007, 68, 794-800.	0.4	176
232	Systemic Chemotherapy and Two-Stage Hepatectomy for Extensive Bilateral Colorectal Liver Metastases: Perioperative Safety and Survival. Journal of Gastrointestinal Surgery, 2007, 11, 1498-1505.	0.9	149
233	Anal Cancer: Current and Future Methodology. Cancer Investigation, 2006, 24, 535-544.	0.6	42
234	Clinical and Pathologic Predictors of Locoregional Recurrence, Distant Metastasis, and Overall Survival in Patients Treated With Chemoradiation and Mesorectal Excision for Rectal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2006, 29, 219-224.	0.6	158

#	Article	IF	Citations
235	Phase II study of capecitabine (XelodaÂ®) and concomitant boost radiotherapy in patients with locally advanced rectal cancer. International Journal of Radiation Oncology Biology Physics, 2006, 66, 762-771.	0.4	110
236	Biological agents versus chemotherapy in the treatment of colorectal cancer. Expert Opinion on Pharmacotherapy, 2006, 7, 1251-1271.	0.9	3
237	Chemotherapy Regimen Predicts Steatohepatitis and an Increase in 90-Day Mortality After Surgery for Hepatic Colorectal Metastases. Journal of Clinical Oncology, 2006, 24, 2065-2072.	0.8	1,198
238	Effect of Surgical Margin Status on Survival and Site of Recurrence After Hepatic Resection for Colorectal Metastases. Annals of Surgery, 2005, 241, 715-724.	2.1	966
239	Long-term results using local excision after preoperative chemoradiation among selected T3 rectal cancer patients. International Journal of Radiation Oncology Biology Physics, 2004, 60, 1098-1105.	0.4	184
240	Chemotherapy and radiation of anal canal cancer: the first approach. Surgical Oncology Clinics of North America, 2004, 13, 309-320.	0.6	17
241	The treatment of colorectal carcinoma: standard chemotherapy and beyond. Clinical Advances in Hematology and Oncology, 2004, 2, 592-8.	0.3	1
242	Colorectal cancer during pregnancy or postpartum: Case series and literature review. Obstetric Medicine, 0, , 1753495X2110412.	0.5	4
243	Rare development of bone metastases in appendiceal epithelial neoplasm: case report. Research, 0, 1, .	0.0	0